Literature DB >> 15905494

Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection.

Clay Beauregard1, Christina Stevens, Elizabeth Mayhew, Jerry Y Niederkorn.   

Abstract

A large body of evidence suggests that corneal allograft rejection is mediated by a type 1 Th cell response and that deviation toward type 2 immunity favors graft survival. However, clinical observations indicate that patients with severe ocular allergies have increased risk of corneal allograft rejection. We used a mouse model of atopic conjunctivitis to evaluate the effects of Th2 immune deviation on corneal allograft survival and possible mechanisms of graft rejection. Our results reveal the following novel findings: 1) atopic conjunctivitis promotes systemic Th2 immune responses to corneal graft donor alloantigens; 2) corneal allografts in atopic host eyes have an increased incidence and swifter tempo of rejection; 3) increased rejection is associated with alterations in systemic T cell-mediated responses to donor alloantigens; and 4) corneal allograft rejection in atopic hosts does not require the direct involvement of infiltrating eosinophils.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905494     DOI: 10.4049/jimmunol.174.11.6577

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye.

Authors:  K J Paunicka; J Mellon; D Robertson; M Petroll; J R Brown; J Y Niederkorn
Journal:  Am J Transplant       Date:  2015-04-14       Impact factor: 8.086

Review 2.  Animal models of high-risk corneal transplantation: A comprehensive review.

Authors:  Rohan Bir Singh; Anna Marmalidou; Afsaneh Amouzegar; Yihe Chen; Reza Dana
Journal:  Exp Eye Res       Date:  2020-07-25       Impact factor: 3.467

3.  IFN-γ blocks CD4+CD25+ Tregs and abolishes immune privilege of minor histocompatibility mismatched corneal allografts.

Authors:  K Cunnusamy; J Y Niederkorn
Journal:  Am J Transplant       Date:  2013-10-01       Impact factor: 8.086

Review 4.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

5.  CCL-21 conditioned regulatory T cells induce allotolerance through enhanced homing to lymphoid tissue.

Authors:  Sunil K Chauhan; Daniel R Saban; Thomas H Dohlman; Reza Dana
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 6.  High-risk corneal allografts and why they lose their immune privilege.

Authors:  Jerry Y Niederkorn
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-10

7.  Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival.

Authors:  Svetlana Stanojlovic; Stephan Schlickeiser; Christine Appelt; Katrin Vogt; Isabela Schmitt-Knosalla; Stefanie Haase; Thomas Ritter; Birgit Sawitzki; Uwe Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-06-24       Impact factor: 3.117

8.  Paradigm shifts in the role of CD4+ T cells in keratoplasty.

Authors:  Khrishen Cunnusamy; Peter W Chen; Jerry Y Niederkorn
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

9.  Allergic conjunctivitis renders CD4(+) T cells resistant to t regulatory cells and exacerbates corneal allograft rejection.

Authors:  N J Reyes; P W Chen; J Y Niederkorn
Journal:  Am J Transplant       Date:  2013-03-13       Impact factor: 8.086

Review 10.  New twists to an old story: novel concepts in the pathogenesis of allergic eye disease.

Authors:  Daniel R Saban; Virginia Calder; Chuan-Hui Kuo; Nancy J Reyes; Darlene A Dartt; Santa J Ono; Jerry Y Niederkorn
Journal:  Curr Eye Res       Date:  2013-01-02       Impact factor: 2.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.